News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MMMW 5 yrs.
https://www.stockscores.com/chart.asp?TickerSymbol=MMMW&TimeRange=1600&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&avgType1=&movAvg1=&avgType2=&movAvg2=&candles=redgreen
[-chart]www.stockscores.com/chart.asp?TickerSymbol=MMMW&TimeRange=1600&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&avgType1=&movAvg1=&avgType2=&movAvg2=&candles=redgreen[/chart]
I wish you and everyone & your family a very happy & prosperous New Year 2018!!!
$PMCB Checking in on Signals for Pharmacyte Biotech Inc. (PMCB) PMCB
http://yankeeanalysts.com/2016/12/20/checking-in-on-signals-for-pharmacyte-biotech-inc-pmcb/
Go $PMCB
$PMCB Traders are Following Technical Levels for Pharmacyte Biotech Inc. (PMCB)
http://yankeeanalysts.com/2016/12/02/traders-are-following-technical-levels-for-pharmacyte-biotech-inc-pmcb/
$PMCB PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial
http://www.einnews.com/pr_news/356234849/pharmacyte-biotech-moves-closer-to-enrolling-patients-in-pancreatic-cancer-clinical-trial
$PMCB OTC Stock Worth Mentioning Today: Investors Looking Closely at PHARMACYTE BIOTECH INCORPORATED (PMCB)
http://www.whatsonthorold.com/2016/11/17/otc-stock-worth-mentioning-today-investors-looking-closely-at-pharmacyte-biotech-incorporated-pmcb/
$PMCB A Long Game of Patience in Pharmacyte Biotech Inc (OTCMKTS:PMCB)
http://oracledispatch.com/2016/09/19/a-long-game-of-patience-in-pharmacyte-biotech-inc-otcmktspmcb/
$MMMW Daily & Weekly Chart
$MMMW Daily Chart
$MMMW Daily & Weekly Charts
$MMMW Daily and Weekly Ichimoku Chart
$PMCB Cardica News and Response Bodes Well for Pharmacyte Biotech
Cardica, Inc. (NASDAQ:CRDC) has given the market a not-so-gentle reminder that biotechnology and medical devices aren't under the same fire as biopharmaceuticals. Time to put Pharmacyte Biotech Inc. (OTCMKTS:PMCB) back on the radar, for the same reason.
After more than a year's worth of miserable performance from the stock, Cardica, Inc. (NASDAQ:CRDC) shares are soaring, up 36% today on the heels of news that its surgical stapling device has been cleared by the FDA for far more uses than had been previously permitted. The news doesn't come as a complete shock to CRDC owners, though that's certainty didn't start to materialize until after January 7th when the company announced a new partnership agreement with Intuitive Surgical that vaguely suggested good news was on the way. And, even the inkling of good news didn't do as much for Cardica shares as the confirmed news did this morning.
In a bigger sense, while pharmaceuticals and specialty drugs were under fire during the latter half of 2015, that weakness also unfairly pressured makers of biotech devices lower. The rebound from CRDC helps to imply the group is in rebound mode now, so for investors looking to pick up other compelling but speculative biotech device ideas may want to add Pharmacyte Biotech Inc. (OTCMKTS:PMCB) if not their portfolio.
Pharmacyte Biotech is the developer of a biotechnology called Cell-In-a-Box, which is making the healthcare industry rethink what's possible in terms of drug delivery.
Pharmacyte Biotech has, in simplest terms, perfected the elusive art of live cell encapsulation. In other words, PMCB is successfully doing what most researchers and biotech companies have struggled to do well (and been unable to do for the long haul) by encapsulating live cells in a package that (1) is small enough to be implanted into a human body, (2) durable enough to resist a body's immune response, and (3) porous enough to allow the healthy cells living inside the encapsulation to operate normally when that patient's own cells aren't doing their job. Cell-in-a-Box is that biotechnology.
It's as much of a process as it is a molecular structure. The first step in their creation is a mix of live cells (that ultimately spur or even become the therapy) and a proprietary polymer that is then dropped into another proprietary polymer. The two polymers react to form a solid object about the size of the head of the pin, with the still-living cells beneath the shell of the tiny sphere. Though only a few millimeters across, the number of living cells inside the tiny bead-sized capsule can be in the thousands.
While it's not a new idea, Pharmacyte has upped the ante, so to speak, on encapsulation. These capsules allow the cells inside to receive nutrients from a body as well as emit certain chemicals, yet they don't let antibodies in and potentially kill the outside, unrecognized cells the way an immune system normally would. And, unlike most other encapsulation efforts, the capsule itself isn't known to degrade.
The implications for such a technology are almost limitless, although Pharmacyte is first focusing on two arenas... pancreatic cancer, and type 1 diabetes.
On the diabetes front, the cells "in the box" would be insulin-producing engineered Magellan cells inside the pinhead-sized beads, which are then surgically deposited in the leg, near the bloodstream. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
As for pancreatic cancer, Cell-in-a-Box is a means of placing thousands of live cells that produce a P450 enzyme inside the capsule, which can activate an otherwise inactive form of cancer drug ifosfamide to produce an anti-cancerous effect.
The upside to this approach is pin-point placement.
Ifosfamide in its active form is usually delivered intravenously and then activated in the liver. The process "works", but much of the drug doesn't make it to the pancreas. To deliver a dose big enough to make a dent in a pancreatic tumor, nasty side effects are almost a given. The Cell-in-a-Box approach circumvents this inefficient form of delivery by inserting encapsulated P450-producing cells very near the tumor itself, which means ifosfamide isn't activated until it's at or near the pancreatic tumor, which means the bulk of the drug is delivered where it needs to be delivered. This in turn means less of the drug is necessary to produce a response. Less of a drug means fewer side effects, without giving up efficacy.
It blurs the line between biotechnology device and biopharmaceuticals... as most next-generation treatments should.
Though there's still more work to be done, as most veteran traders can attest, the market rewards biotech companies reaching milestones by pushing the stock upward. The PMCB premise alone already has plenty of people interested, and with 2016 being a year with lots of catalysts in the queue, now's the time to start taking a closer look.
With that in mind, just this morning the company updated its explanation of its biotechnology and added some new information about Cell-In-a-Box. Newcomers as well as those familiar with Pharmacyte Biotech will want to take a look right here.
http://money.cnn.com/news/newsfeeds/articles/globenewswire/6150096.htm
$PMCB PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs
SILVER SPRING, Md., Dec. 30, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today a shareholder update on PharmaCyte’s pancreatic cancer and diabetes programs.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, highlighted the following developments since the Company’s last shareholder update:
PharmaCyte announced a complete redesign of its clinical trial in advanced pancreatic cancer. After consulting with world-renowned experts in the filed of pancreatic cancer; including, Dr. Mathias Löhr, Dr. Manuel Hidalgo, and experts at Translational Drug Development (TD2), PharmaCyte’s Phase 2b clinical trial was completely redesigned in an attempt to satisfy a critical unmet medical need that exists for patients with inoperable, but not metastatic, pancreatic cancer whose tumors no longer respond after 4 to 6 months of treatment with the current “gold standard” for the disease, the combination of Abraxane® plus gemcitabine. In most cases, therapy consisting of another chemotherapy agent plus radiation is given to such patients. However, the beneficial effects of these treatments are marginal at best.
The clinical trial will now be conducted in the United States by TD2 with study sites in both Europe and Australia.
Eligible patients will be randomly placed into two groups. Group 1 will receive PharmaCyte’s pancreatic cancer treatment of Cell-in-a-Box® plus low doses of ifosfamide. Group 2 will receive treatment with the combination of capecitabine + radiation.
The primary endpoints for the trial will be: (i) progression-free survival (PSF); and (ii) the side effects that occur in the patients. PSF is the time that elapses from the first day of treatment until the disease gets worse. The trial design also includes several secondary endpoints; the most important of which are: (i) the onset of pain and the patient’s need for pain medications; (ii) whether the inoperable tumors become operable as a result of the treatment; (iii) the change in tumor size; and (iv) the patients’ overall quality of life during the treatment.
PharmaCyte will now include in this trial the evaluation of its pancreatic cancer treatment on the treatment of pain, a severe consequence of pancreatic cancer. A separate clinical trial on pancreatic cancer pain is no longer necessary.
Regarding PharmaCyte’s work on ascites fluid production and accumulation, a series of additional preclinical studies has been initiated and are being continued by TD2. The initial studies using an ovarian tumor model in mice indicated that PharmaCyte’s pancreatic cancer treatment might have value in treating the malignant ascites fluid condition. These preclinical studies are now being continued with other abdominal tumor models, beginning with colon cancer, in an effort to better define the conditions under which PharmaCyte’s pancreatic cancer treatment can modulate the production or accumulation of malignant ascites fluid.
In late 2015, PharmaCyte obtained the Orphan Drug designation (ODD) for its pancreatic cancer treatment from the European Medicines Agency (EMA). With this designation, PharmaCyte now has ODD in Europe and the United States, which was obtained in late 2014 when the FDA granted the ODD to PharmaCyte. Obtaining the ODD allows for 10 years of marketing exclusivity in the European Union and 7 years of marketing exclusivity in the United States upon approval by the EMA and the FDA of PharmaCyte’s pancreatic cancer treatment.
PharmaCyte appointed Dr. Manuel Hidalgo as a member of its Scientific Advisory Board and as a consultant. For several years, Dr. Hidalgo worked closely with pancreatic cancer expert Dr. Daniel D. Von Hoff, Chief Development Officer of TD2. Recently, Dr. Hidalgo was appointed Head of Hematology and Oncology at the Beth Israel Deaconess Hospital in Boston, an institution that is affiliated with the renowned Dana-Farber Cancer Institute in Boston.
PharmaCyte contracted with Imaging Endpoints, one of America’s leading Contract Research Organizations for radiologic imaging, to perform the radiologic imaging that will be the cornerstone of many of the measurements conducted during the pancreatic cancer clinical trial.
Prior to the initiation of a clinical trial, an Investigational New Drug Application (IND) must be filed and reviewed by the FDA. A major part of the IND is a section termed “Chemistry, Manufacturing and Controls” or “CMC.” Within the CMC section, a pivotal portion describes the characteristics of the drug or treatment production facility and supplies supporting documentation to ensure that the facility meets cGMP standards. PharmaCyte retained CMC experts Chamow and Associates (Chamow) to assist in evaluating the facility in Bangkok, Thailand, that will produce and supply the Cell-in-a-Box® technology for PharmaCyte’s clinical trial, and in preparing the relevant portions of the CMC section of the IND for submission to the FDA and other regulatory agencies. PharmaCyte and TD2 are awaiting receipt of Chamow’s audit report to finalize the timeline for commencement of the clinical trial.
In November 2015, the second annual meeting of the international Diabetes Consortium was held in Vienna, Austria. Members of the Consortium presented results of studies done to date and finalized research plans for future studies. A video that discusses PharmaCyte’s diabetes program was filmed at the meeting and can be viewed at www.PharmaCyte.com/diabetes.
A guest at the meeting of the Diabetes Consortium was Prof. Dr. Hans-Peter Hammes, one of Europe’s leading authorities on diabetes and its complications. Dr. Hammes currently serves as Section Head of Endocrinology at the 5th Medical Department, University Medical Center Mannheim at the University of Heidelberg in Germany. Dr. Hammes received the prestigious Camillo Golgi Prize awarded at the 2015 meeting of the European Association for the Study of Diabetes. After attending the Diabetes Consortium meeting and becoming acquainted with the Consortium members, Dr. Hammes agreed to join PharmaCyte’s Scientific Advisory Board and become a member of the Consortium. Dr. Hammes also agreed to serve as a consultant to PharmaCyte.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
$MMMW & $PMCB Duel Charts
$PMCB If You Like Islet Sciences, You'll Love Pharmacyte Biotech
Islet Sciences Inc. (OTCMKTS:ISLT) shares were all the rage on Monday, but Pharmacyte Biotech Inc. (OTCMKTS:PMCB) remains one of the market's most compelling penny stocks in the diabetes treatment space.
Congratulations to anyone who happened to own Islet Sciences Inc. (OTCMKTS:ISLT) before Friday's close. ISLT shares shot out of the gate on Monday morning, end the day with a 250% gain... proving penny stocks can and do pay off when the timing and story is right. If you're serious about tapping into the next era of diabetes treatments, though, then you may want to lock in what you can while you can with Islet Sciences and then take a closer look at Pharmacyte Biotech Inc. (OTCMKTS:PMCB). It's developing a novel diabetes therapy of its own, and could change the way we think about treating the dreaded disease.
Don't look for any particular reason something news-related lit a fire under ISLT on Monday - you won't find it. Sometimes penny stocks just strike the right cord with the right group of people and develop a life of their own.
That's not to take away from the work Islet Sciences has done. It's work in the area of creating immune-modulating drugs that protect insulin-producing beta-cells from cytokines responsible for cell destruction has been eye-opening, and shows promise. Specifically, Islet Sciences Inc. has found that microencapsulated -- protected -- porcine islets injected into the abdominal cavity can effectively serve as a transplanted pancreas for diabetic patients. What's not clear is the longevity of the encapsulated cells. In trials this far, 85% of transplantees remained insulin-independent at the one-year mark, but a 15% attrition rate in just the first year doesn't necessarily bode well as a long-term fix given the surgery involved.
It's akin to an approach Pharmacyte Biotech is taking to treat diabetes as well, but perhaps with a little more promise.
The technology is called Cell-in-a-Box. Pharmacyte Biotech developed it as a means of depositing living, normally-functioning cells into a particular part of the body where their presence would have a therapeutic effect. In this case, the cells "in the box" would be insulin-producing islet cells placed in the leg near the bloodstream. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
The key is the polymer used to encapsulate living cells.
The manufacturing process begins with the mix of live cells (insulin-producing Melligen cells, in this case) and a polymer which are sent through a droplet-forming machine and into a small vat of another proprietary polymer. When the two polymers join, a membrane is formed, with the living cells inside of it. This shell keeps the cells inside, yet lets insulin out, while allowing nutrients in, and waste out. Most important though, the shell keeps the body's own immune system from killing these cells.... something most previous encapsulation approaches didn't do. A handful of these pinhead-sized capsules containing Melligen cells can replace the insulin-producing function of the pancreas from some other site in the body.
Cell-in-a-Box as a therapy for type 1 diabetes is currently in the preclinical testing phase, although it was recently determined to be safe as a means of treating type 1 diabetes by the University of Veterinary Medicine Vienna. Based on the results witnesses in the preliminary studies at the university, the company aims to move forward with plans that will ultimately result in human trials
It's a major leap forward for diabetics - an encapsulation biotechnology that actually works for the long haul.
There's still work to be done. Cell-in-a-Box as a treatment pathway for type 1 diabetes is currently in the preclinical testing phase, although it was recently determined to be safe as a means of treating type 1 diabetes by the University of Veterinary Medicine Vienna. Based on the results witnesses in the preliminary studies at the university, the company aims to move forward with plans that will ultimately result in human trials.
And yes, though still in preclinical testing, the premise has been proven safe.
The work will be worth the effort. The diabetes treatment market is worth an estimated $7 billion per year, and Cell-in-a-Box is effectively a cure for it that abates the need for needles. In the meantime, investors are apt to reward the stock as the company achieves critical milestones en route to the endzone.
None of this is to take away from what Islet Sciences has done, or any other penny stocks of companies working on diabetes therapies. All that other work, however, underscores just how game-changing PMCB could be in the world of diabetes.
A leading killer of OTC stock prices is "floorless convertible debt", also known as "Death Spiral Financing"
This Board is now accepting nominations of OTC public companies to be verified of having no floorless convertible debt. Please send your request for nominations as a message post. As of August 8,2016 thirty eight requests for nominations for verification as the first step in the process have been approved. More nomination are expected shortly.
Congratulations to the following companies
nominated for verification review of having no floorless toxic convertibles are;
Mass Megawatts Wind Power, Inc (MMMW)
Iteknik Holding Corporation (ITKH)
United American Petroleum (UAPC)
Valmie Resources, Inc. (VMRI)
Cardica, Inc. (CRDC)
Sunset Capital Assets, Inc. (SNST)
Players Network (the)(PNTV)
Boreal Water Collection, Inc. (BRWC)
Gazprom Oao (OGZPY)
Kiwa-Bio-Tech Products Group (KWBT)
Pharmacyte Biotech, Inc. (PMCB)
Jns Holdings Corporation (JNSH)
Mmrglobal,Inc. (MMRF)
Fitbit, Inc. (FIT)
One World Holdings,Inc. (OWOO)
International Spirit and Beverage Group, Inc.(ISBG)
Stratasys, LTD (SSYS)
CMG Holdings Group, Inc. (CMGO)
Royale Energy,Inc. (ROYL)
On4 Communications, Inc. (ONCI)
Polaris International Holdings, Inc. (PIHN)
Discovery Minerals, LTD (DSCR)
Well Power,Inc. (WPWR)
Tungsten Corp. (TUNG)
Zalemark Holdings Co., Inc. (ZMRK)
Daniels Corporate Advisory Co, Inc. (DCAC)
Idglobal Corp. (IDGC)
National Energy Services, Inc. (NESV)
Ism International, Inc. (ISML)
Praxsyn Corporation (PXYN)
Cannabis Science. Inc. (CBIS)
India Ecommerce Corp. (IEEC)
Q Lotus Holdings Inc. (QLTS)
New Wave Holdings, Inc. (NWAV)
Global Equity International (GEQU)
New America Energy Corp. (NECA)
Medical Marijuana, Inc. (MJNA)
Mike the Pike Productions, Inc. (MIKP)
The following information is from the United States Securities and Exchange Commission website articulating the risk related to Convertible Debt
A "convertible security" is a security—usually a bond or a preferred stock—that can be converted into a different security—typically shares of the company's common stock. In most cases, the holder of the convertible determines whether and when to convert. In other cases, the company has the right to determine when the conversion occurs.
Companies generally issue convertible securities to raise money. Companies that have access to conventional means of raising capital (such as public offerings and bank financings) might offer convertible securities for particular business reasons. Companies that may be unable to tap conventional sources of funding sometimes offer convertible securities as a way to raise money more quickly. In a conventional convertible security financing, the conversion formula is generally fixed - meaning that the convertible security converts into common stock based on a fixed price. The convertible security financing arrangements might also include caps or other provisions to limit dilution (the reduction in earnings per share and proportional ownership that occurs when, for example, holders of convertible securities convert those securities into common stock).
By contrast, in less conventional convertible security financings, the conversion ratio may be based on fluctuating market prices to determine the number of shares of common stock to be issued on conversion. A market price based conversion formula protects the holders of the convertibles against price declines, while subjecting both the company and the holders of its common stock to certain risks. Because a market price based conversion formula can lead to dramatic stock price reductions and corresponding negative effects on both the company and its shareholders, convertible security financings with market price based conversion ratios have colloquially been called "floorless", "toxic," "death spiral," and "ratchet" convertibles.
Both investors and companies should understand that market price based convertible security deals can affect the company and possibly lower the value of its securities. Here's how these deals tend to work and the risks they pose:
 | The company issues convertible securities that allow the holders to convert their securities to common stock at a discount to the market price at the time of conversion. That means that the lower the stock price, the more shares the company must issue on conversion. |
| The more shares the company issues on conversion, the greater the dilution to the company's shareholders will be. The company will have more shares outstanding after the conversion, revenues per share will be lower, and individual investors will own proportionally less of the company. While dilution can occur with either fixed or market price based conversion formulas, the risk of potential adverse effects increases with a market price based conversion formula. |
| The greater the dilution, the greater the potential that the stock price per share will fall. The more the stock price falls, the greater the number of shares the company may have to issue in future conversions and the harder it might be for the company to obtain other financing. |
Before you decide to invest in a company, you should find out what types of financings the company has engaged in - including convertible security deals - and make sure that you understand the effects those financings might have on the company and the value of its securities. You can do this by researching the company in the SEC's EDGAR database and looking at the company's registration statements and other filings. Even if the company sells convertible securities in a private, unregistered transaction (or "private placement"), the company and the purchaser normally agree that the company will register the underlying common stock for the purchaser's resale prior to conversion. You'll also find disclosures about these and other financings in the company's annual and quarterly reports on Forms 10-K and 10-Q, respectively, and in any interim reports on Form 8-K that announce the financing transaction.
If the company has engaged in convertible security financings, be sure to ascertain the nature of the convertible financing arrangement - fixed versus market price based conversion ratios. Be sure you fully understand the terms of the convertible security financing arrangement, including the circumstances of its issuance and how the conversion formula works. You should also understand the risks and the possible effects on the company and its outstanding securities arising from the below market price conversions and potentially significant additional share issuances and sales, including dilution to shareholders. You should be aware of the risks arising from the effects of the purchasers and other parties trading strategies, such as short selling activities, on the market price for the company's securities, which may affect the amount of shares issued on future conversions.
Companies should also understand the terms and risks of convertible security arrangements so that they can appropriately evaluate the issues that arise. Companies entering into these types of convertible securities transactions should understand fully the effects that the market price based conversion ratio may have on the company and the market for its securities. Companies should also consider the effect that significant share issuances and below market conversions have on a company's ability to obtain other financing.
Companies or investors seeking to learn more about the SEC's registration requirements for common stock issuable upon conversion of unregistered convertible securities, including the timing of the filing of the resale registration statement and the appropriate form that the company may use to register the resale, should consult the Division of Corporation Finance's Compliance and Disclosure Interpretations.
Bloomberg follow up on DEATH SPIRAL FINANCING- incredible article.
Remember, Bloomberg did a first article about "Magna" and Josh Sason who runs it- how they provide financing to cash desperate penny stocks (such as Bioheart, BHRT which has a forum here on I-HUB and did qty-2 Magna financing deals end of 2014).
This was Bloombergs first excellent piece of financial journalism- where a highly reputable main stream financial news and investigative journalism group looked into the sorted world of what's known as "death spiral" or "floorless convertible debt" as is discussed here.
Here's that first article:
http://www.bloomberg.com/news/articles/2015-03-12/josh-sason-made-millions-from-penny-stock-financing
Here is the latest article- written by a Bloomberg writer (and this guy is no duffer, look at his resume on the upper right-hand column: Investment banker, mergers and acquisitions lawyer among other attributes on a very flush, "expert" quality resume)
Here's his follow up on the first Bloomberg piece- it's an incredible glimpse, with explanations, into the sorted world of penny stock "death spiral" financing and how it all works. A stunning read IMO. Amazing stuff that some news source as credible as Bloomberg is finally peeling back the layers and revealing this sorted, dark world of penny stock financing IMO- real amazing read:
http://www.bloombergview.com/articles/2015-03-12/death-spiral-convertible-financier-has-a-lot-of-fun
An amazing read IMO- another "best of" in explaining some of the inner workings of the "convertible debt" dark recesses of the penny stock finance world.
